Supported Releases: These releases have been certified by Bloomberg’s Enterprise Products team for use by Bloomberg customers. Experimental Releases: These releases have not yet been certified for use ...
Susan Dziubinski: Well, it’s time for our question of the week. Now, as a reminder, the best way to get your question answered is to email us at [email protected]. This week’s question ...
Veeva Systems, which offers life sciences companies cloud-based commercial management software and business consulting services, is venturing into the consumer-facing side of things with the ...
Veeva Systems has built its presence in brand engagement with the acquisition of Ostro, a tech start-up that helps pharma companies connect with doctors and patients using AI-powered conversational ...
Veeva Systems acquired Ostro, a platform that offers an artificial intelligence-driven chatbot for patients and doctors, in a deal valued at $100 million. The life sciences software and data company ...
The deal signals Veeva’s push to expand artificial intelligence tools that help pharmaceutical brands interact with patients and healthcare professionals. The transaction adds an AI-powered engagement ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Veeva's laser focus on the life sciences industry has made it a leader in this corner of the cloud market. The company could grow its revenue -- and share price -- at a good clip in the next four ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
As noted previously, when Veeva ended its licence agreement with Salesforce, it not only triggered a battle royale for domination of big pharma CRM, it began the first massive use case for adoption of ...
Veeva Systems (NYSE: VEEV) is currently in Phase 18, the final stage of its 18-phase Adhishthana cycle on the weekly charts. The company recently reported earnings, and the stock has fallen sharply ...
As Veeva and Salesforce go their separate ways, why it's all to play for in the Life Sciences market
Our CRM business is healthy, and it is an important part of Veeva, but it's not the major -- it's not the largest part of Veeva anymore, that’s for sure. A significant statement from Peter Gassner, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results